Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Praluzatamab Ravtansine(一种靶向 CD166 的抗体药物偶联物)用于治疗晚期实体瘤患者:一项开放标签 I/II 期试验
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-21-3656
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, G